Market cap
$378.8m
End-of-day close multiplied by current shares on issue.
PEB · NZX
Pacific Edge is an NZX-listed healthcare / diagnostics company with FY24 - HY26 of published result briefings.
Snapshot
HY26, released 25 November 2025
| Metric | Value | Change |
|---|---|---|
| Revenue | $5.9m | ↓ -45.8% |
| NPAT | -$19.1m | ↓ -31.7% |
| Operating cash flow | -$19m | ↓ -52.5% |
| Net debt | -$14.8m | ↑ +31.5% |
| ROE % | -71.0% | ↓ -35.3pp |
| PBT | -$19.1m | ↓ -31.7% |
| FCF pre-lease | -$19.1m | ↓ -46.8% |
| Inventory days | 119 | ↑ +167.0% |
| Total assets | $34.7m | ↓ -31.8% |
Source: latest published briefing (HY26, released 25 November 2025). Change compares against the prior equivalent period: HY25, released 26 November 2024.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$378.8m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.03
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
14.08x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Chat
Ask follow-up questions about Pacific Edge's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | HY266 MONTHS25 November 2025 | FY2512 MONTHS30 May 2025 | HY256 MONTHS26 November 2024 | FY2412 MONTHS21 May 2024 | Trend |
|---|---|---|---|---|---|
| Revenue | $5.9m | $21.8m | $11m | $23.9m | Chart |
| Revenue growth % | -45.8% | -8.6% | -16.3% | 21.9% | Chart |
| PBT | -$19.1m | -$29.9m | -$14.5m | -$29.5m | Chart |
| NPAT | -$19.1m | -$29.9m | -$14.5m | -$29.5m | Chart |
| Operating cash flow | -$19m | -$24.7m | -$12.5m | -$25.8m | Chart |
| FCF pre-lease | -$19.1m | -$26m | -$13m | -$27.1m | Chart |
| ROE % | -71.0% | -114.8% | -35.7% | -43.0% | Chart |
| Net debt | -$14.8m | -$9.2m | -$21.6m | -$29m | Chart |
| Debtor days | — | 47 | — | 39 | Chart |
| Inventory days | 119 | 27 | 45 | 26 | Chart |
| Total assets | $34.7m | $37m | $50.9m | $65.4m | Chart |
Reference: annolyse.ai/companies/peb
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Statutory profit after tax.
Cash generated from operations.
Operating cash flow less capex before leases.
Return on equity.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Borrowings less cash; negative values indicate net cash.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From Cash falls 67.6% to NZ$9.5M as revenue drops 8.6% on Medicare uncertainty
No formal financial guidance has been provided, so there is no numeric target against which to assess FY25. Management's stated framing — a "holding pattern" awaiting Medicare resolution — implies that FY25 results are not intended to represent a normalised run rate. The APAC contribution and sales force efficiency gains are cited as partial offsets, and US Tests/Sales FTE improved 6.4% in Q4 FY25 versus Q4 FY24, suggesting some operational recovery in the final quarter.
However, the absence of a clear Medicare resolution timeline means the path to cash-flow neutrality is undefined. The second-half revenue of NZ$10.9M being marginally below the first-half NZ$11.0M does not support a "sequential improvement" narrative, and the closing cash position means the company will need either a step-change in revenue or an external capital event in the near term.
Open questions
This briefing cannot assess whether Pacific Edge's cash position is sufficient to reach a Medicare decision, nor can it evaluate the probability or timing of that regulatory outcome.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
HY26 · Released 25 November 2025
Pacific Edge's HY26 operating loss widened to NZ$19.1M after Medicare coverage was withdrawn, with just NZ$15.1M cash remaining to fund an ongoing
FY25 · Released 30 May 2025
Pacific Edge burned NZ$24.7M in operating cash in FY25, leaving a closing balance of NZ$9.5M that raises immediate questions about runway without a
HY25 · Released 26 November 2024
Loss narrowed just 4.9% despite a smaller cost base, leaving $21.9m of cash against a $12.5m half-year operating burn.
FY24 · Released 21 May 2024
Cash burn held near $25.8m while equity eroded 34% to $54.6m, leaving runway as the central question on a still loss-making business.
Get the next Pacific Edge result briefing and five-year history updates by email.